Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | Current treatment strategies for newly diagnosed Hodgkin lymphoma

David Straus • 18 Aug 2020
SOHO 2020
Hodgkin Lymphoma Lymphoma Bleomycin Dacarbazine Doxorubicin Vinblastine

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the current treatment strategies in newly diagnosed Hodgkin lymphoma, and explores the use of radiotherapy in some patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Straus

IVAC +/- rituximab in R/R B-NHLs: a real-world data review
6:38
IVAC +/- rituximab in R/R B-NHLs: a real-world data review
David Straus • 2 Dec 2020
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
8:50
Brentuximab vedotin in treatment naïve cHL patients: a 5-year update of the ECHELON-1 trial
David Straus • 2 Dec 2020
R/R lymphoma: checkpoint blockade and transplantation
2:34
R/R lymphoma: checkpoint blockade and transplantation
David Straus • 18 Aug 2020
Treatment of bulky stage I/II lymphoma
3:24
Treatment of bulky stage I/II lymphoma
David Straus • 18 Aug 2020

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
David Straus • 6 Dec 2025
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
2:10
Impact of bridging therapy on efficacy of CD19 CAR T-cell therapy in DLBCL
David Straus • 8 Dec 2025
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
2:42
Phase II results of rituximab and epcoritamab as 1L therapy for patients with high-tumor-burden FL
David Straus • 8 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
David Straus • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals